Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: VLAD who wrote (13508)	8/17/1998 6:34:00 PM
From: DaiS	Respond to of 23519

Vlad, IMO we have, for viagra, just about reached the equilibrium to which you refer. It is curious that the numbers of news and refills are roughly equal for viagra just as they now are for muse. Moroever, muse/viagra has also reached an asymptote with muse getting roughly 2.5% of the total scripts. I have a strong suspicion that just about every man who had any strong desire to try viagra has now done so, and that the new scripts are from regulars, just as with muse - the time scale for viagra has simply been telescoped. Is this consistent with what you know about the way viagra is prescribed? Presumably only advertising and marketing can now change this picture. The picture must puzzle analysts who expected viagra to bring muse scripts to zero. I would be puzzled, and I would think, funny Vivus have not got a marketing partner yet, with that they might do well. DaiS